Refine Your Search

  • Solutions

  • Therapeutic Areas

  • Resource Type

Certara’s Best of the Blog 2017

A selection of short essays from our blog, written to empower our customers with modeling and simulation (M&S) and regulatory writing solutions in order to help them solve the toughest drug development problems. Certara staff contributions range in topic from pharmacometrics to systems biology to the growing importance of regulatory writing and sharing clinical trial results.

Author(s): Alice Ke, Andrzej Kierzek, Angela Colbers, Barry Mangum, Behtash Bahador, David Turner, Ellen Leinfuss, Graham Scott, Iain Gardner, Julie Bullock, Leon Bax, Lora Killian, Maria Saluta, Nathan Teuscher, Nirpal Singh Virdee, Oliver Hatley, Peter Bonate, Rob Connelly, Ronette Gehring, Shriram Pathak, Shuhua Hu, Stacey Tannenbaum, Steve Sibley, Suzanne Minton, Tom Snowden
Solution: Clinical Pharmacology Strategy, Clinical Transparency & Disclosure, Clinical Trials Simulation, Drug Development & Regulatory Strategy, Model-based Meta-analysis, PBPK Modeling & Simulation, PK/PD Modeling & Simulation, Regulatory & Medical Writing, Scientific Informatics, Systems Pharmacology
Therapeutic Area: Central Nervous System, Infectious Disease, Oncology/Hematology, Pediatrics, Rare/Orphan Disease
More Info

How MBMA Can Help You Make Smarter Drug Development Decisions

Successful drug development depends on making wise decisions about portfolios, clinical trials, marketing, etc. We’re continuously faced with the challenge of deciding whether to continue development or stop it. To support those decisions, we gather data, typically through clinical trials. We analyze the data from those clinical trials, and then we use these analyses to […]

Solution: Model-based Meta-analysis, PK/PD Modeling & Simulation
More Info

Using Model-based Meta-analysis to Improve Decision-making in Drug Development

Making the right choices in drug development often means the difference between getting a new medication to patients and it ending up in the scrap heap of failed programs. There is a surfeit of publicly available information on approved drugs as well as those currently in development. How can sponsors turn clinical trial data into understanding that helps chart the course for investigational drugs?

Speaker(s): Leon Bax
Solution: Model-based Meta-analysis, Model-informed Drug Development, PK/PD Modeling & Simulation
Therapeutic Area: Cardiovascular, Endocrinology
More Info